GA
AXGN icon

Geneva Advisors’s Axogen AXGN Stock Holding History

Geneva Advisors’s Portfolio AXGN Stock Details AXGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,000
Closed -$54K – 727
2016
Q1 		$54K Buy
+10,000
New +$50.8K ﹤0.01% 664
2014
Q1 		– Sell
-10,000
Closed -$45K – 691
2013
Q4 		$45K Buy
+10,000
New +$40.6K ﹤0.01% 524

Other funds holding AXGN

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Geneva Advisors's AXGN Position: Q2 2016 in Review

Geneva Advisors sold out of Axogen (AXGN) in Q2 2016, closing a stake of 10,000 shares — an estimated $54K sold.

Geneva Advisors first reported a position in AXGN in Q4 2013 and held it in 2 quarters. The position peaked at $54K in Q1 2016. 67 funds tracked by Wall St. Rank hold AXGN as of Q2 2016.

  • Geneva Advisors reported no remaining Axogen position as of Q2 2016 after selling out during the quarter.
  • Geneva Advisors sold 10,000 Axogen shares in Q2 2016, an estimated $54K.
  • Geneva Advisors first reported a position in Axogen in Q4 2013 and held it in 2 quarters.
  • Geneva Advisors's Axogen position peaked at $54K in Q1 2016.
  • 67 funds tracked by Wall St. Rank held Axogen as of Q2 2016.

Based on Geneva Advisors's 13F filing for Q2 2016, filed 8 Aug 2016.